The economics of Health AI: understanding where value truly lies

The conversation around Artificial intelligence (AI) in healthcare has, in recent years, been shaped by a largely optimistic economic narrative. AI is expected to improve efficiency, reduce costs, and enhance outcomes often simultaneously.

From automated diagnostics to predictive analytics and workflow optimisation, the assumption is that innovation will naturally translate into economic value.

This assumption, while intuitive, is incomplete.

As John Maynard Keynes once observed, “the difficulty lies not so much in developing new ideas as in escaping from old ones.” The expectation that innovation will automatically translate into economic value reflects precisely such an inherited assumption one that does not fully account for the institutional realities of healthcare systems.

The economics of Health AI is not defined solely by efficiency gains. It is shaped by how value is created, distributed, and sustained across complex healthcare systems, systems that are inherently multi-actor, resource-constrained, and institutionally layered.

AI does not simply reduce costs. It reorganises them.

At the point of deployment, AI introduces new layers of expenditure that are often under-accounted for in early-stage projections.

These include investments in data infrastructure, system integration, cybersecurity, regulatory compliance, and ongoing model monitoring. Unlike traditional technologies, many AI systems are not static. They require continuous updating, validation, and recalibration, creating a possible recurring cost structure rather than a one-time investment.

These costs are not merely additive; they reshape opportunity costs within healthcare systems. Resources allocated toward AI infrastructure and integration are, in many cases, diverted from other areas of care, making the economic case dependent not only on efficiency gains, but on comparative value across competing priorities.

This shifts the economic baseline.

Beyond access: why digital health requires critical engagement in the age of AI

In parallel, AI redistributes value across stakeholders in ways that are not always immediately visible. Technology developers capture value through intellectual property and platform control. Healthcare providers may benefit from efficiency gains, but often absorb the costs of integration and workflow adaptation.

Patients may experience improved access or outcomes, but rarely participate directly in value capture, despite being central to the data ecosystems that enable these systems.

The result is not a uniform increase in value, but a reallocation.

This redistribution introduces a fundamental challenge: misaligned incentives.

This dynamic closely resembles classic principal-agent problems in economics, where those making decisions are not always those bearing the costs or receiving the benefits. In healthcare, this separation is particularly pronounced, complicating the pathway from innovation to value realisation.

Healthcare systems are not neutral environments. They operate through reimbursement structures, budget constraints, and institutional priorities that do not always align with technological innovation.

An AI system that improves long-term outcomes may not generate immediate financial returns for a hospital operating under short-term budget cycles. Similarly, a tool that enhances efficiency in one part of the system may shift costs elsewhere, without clear mechanisms for compensation.

This is one of the reasons many Health AI interventions remain confined to pilot phases.

The issue is not a lack of technological capability.

The realisation of value in Health AI depends not only on what the technology can do, but on how it is integrated into financing models, reimbursement pathways, and institutional decision-making processes. Without this alignment, even high-performing systems struggle to scale.

This is particularly evident in emerging and rapidly digitising markets, where healthcare systems are simultaneously building infrastructure and adopting advanced technologies. In such contexts, the introduction of AI can amplify both opportunity and fragility.

While AI offers pathways to address workforce shortages and improve access, it also introduces dependencies on data systems, technical expertise, and external platforms that may not yet be fully embedded within the health system.

The economics of Health AI, in these settings, becomes inseparable from questions of system readiness.

This raises a broader point. Much of the current discourse around Health AI economics focuses on cost savings and return on investment. These are important metrics, but they capture only part of the picture. They often assume that value is generated at the point of technological deployment.

In practice, value is realised over time and only under certain conditions.

As Adam Smith distinguished between value in use and value in exchange, the utility of a system does not always translate into its economic return. Health AI often delivers significant clinical value, yet struggles to align this with measurable financial outcomes within existing system structures.

It depends on whether systems are trusted and used effectively. It depends on whether workflows are adapted to integrate new tools. It depends on whether governance frameworks support safe and sustained deployment. And critically, it depends on whether the distribution of costs and benefits across stakeholders is understood and managed.

In this sense, the economics of Health AI is less about technology, and more about systems.

This perspective suggests that economic evaluation frameworks need to evolve. Traditional cost-effectiveness analyses may not fully capture the dynamic and distributed nature of AI-driven value. There is a need for approaches that account for lifecycle costs, system-wide impacts, and cross-actor value flows. This includes understanding how investments in infrastructure, training, and governance contribute to long-term returns, even if they do not produce immediate financial gains.

It also requires greater attention to how value is shared.

As data becomes a central asset in healthcare, questions around ownership, access, and benefit distribution become increasingly important. Patients and health systems generate the data that underpin AI systems, yet the economic benefits are often concentrated elsewhere.

Addressing this imbalance is not only a question of equity, but of sustainability. Systems that do not align value with contribution risk undermining trust and long-term adoption.

Beyond principles: the next phase of AI governance in healthcare

At the same time, there is a need to move beyond viewing AI as a discrete product and toward understanding it as part of an evolving ecosystem. AI systems interact with existing technologies, institutional processes, and human actors. Their economic impact cannot be assessed in isolation. It must be understood within the broader context in which they operate.

This is where many current approaches fall short.

Policies and investment strategies often focus on enabling innovation, but less on ensuring that it can be sustained. Funding mechanisms may support pilot programmes, but do not always extend to long-term integration. Regulatory frameworks assess safety and performance, but may not fully engage with economic viability or system-wide impact.

The result is a gap between innovation and implementation.

Bridging this gap requires a more integrated approach one that brings together policy, economics, and system-level understanding. It requires recognising that value in Health AI is not inherent to the technology itself, but emerges from how it is deployed, governed, and embedded within healthcare systems.

For institutions, investors, and policymakers, this represents both a challenge and an opportunity.

Increasingly, this calls for structured approaches that assess not only the technical performance of AI systems, but their economic and institutional fit. This includes examining cost structures, incentive alignment, regulatory pathways, and implementation readiness as part of a coherent strategy.

This is where entities working at the intersection of policy and implementation, including HealthTechAsia, are beginning to focus supporting stakeholders in navigating the economic realities of Health AI, from early-stage evaluation to system-level integration.

As the field continues to evolve, the question is not whether Health AI can create value. It is where that value resides, who captures it, and under what conditions it can be sustained.